Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Oct;136(4):602-611.
doi: 10.1111/bju.16836. Epub 2025 Jul 3.

The role of primary tumour site surgery in metastatic UTUC: a systematic review and meta-analysis

Ludovica Cella #  1   2 , Stefano Moretto #  1   2   3 , Roberto Contieri  4 , Alessandro Uleri  1   2   5 , Pier Paolo Avolio  1   2 , Andrea Piccolini  1   2 , Benedetto Calabrese  1   2 , Vittorio Fasulo  1   2 , Rodolfo Hurle  2 , Massimo Lazzeri  2 , Alberto Saita  2 , Laura S Mertens  6 , Bas W G van Rhijn  6 , Benjamin Pradere  7 , Alexander P Cole  8 , Thomas Seisen  9 , Paolo Casale  1 , Giovanni Lughezzani  1   2 , Nicolò Maria Buffi  1   2 , Marco Paciotti  1   2
Affiliations
Review

The role of primary tumour site surgery in metastatic UTUC: a systematic review and meta-analysis

Ludovica Cella et al. BJU Int. 2025 Oct.

Abstract

Objective: To assess the impact of primary tumour surgery on survival outcomes in patients with metastatic upper urinary tract urothelial carcinoma (mUTUC) by conducting a systematic review and meta-analysis.

Methods: A systematic search was conducted using the PubMed/Medline, Embase, Web of Science, and Cochrane Library databases for studies published up to January 2025, using the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. Eligible studies included adult patients (≥18 years) diagnosed with mUTUC (cM+ excluding cN + M0). The intervention assessed was primary tumour surgery, compared to non-surgical management, including chemotherapy, immunotherapy, radiation therapy, or best supportive care. Key outcomes measured were surgical/peri-operative outcomes, progression-free survival (PFS), cancer-specific survival (CSS) and overall survival (OS).

Results: Ten eligible retrospective studies were identified. Most reported a significant improvement in survival outcomes (PFS, CSS and OS) for patients undergoing primary tumour surgery compared to systemic therapy (STx) alone. Surgery was notably associated with superior OS both for STx plus consolidative surgery (hazard ratio [HR] 0.66, 95% confidence interval [CI] 0.55-0.81) and cytoreductive surgery plus STx (HR 0.73, 95% CI 0.68-0.78). The most favourable outcomes were observed in younger patients and those with a single metastatic site.

Conclusions: Surgery may improve survival outcomes in mUTUC compared to non-surgical options. However, the current evidence is mainly derived from retrospective studies with potential selection bias. Prospective studies are needed to confirm these findings and establish criteria for selecting patients who could benefit from surgical intervention.

Keywords: consolidative surgery; cytoreductive surgery; metastatic upper tract urothelial carcinoma; nephroureterectomy; primary tumor surgery.

PubMed Disclaimer

References

    1. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin 2023; 73: 17–48
    1. Rouprêt M, Seisen T, Birtle AJ et al. European Association of Urology guidelines on upper urinary tract urothelial carcinoma: 2023 update. Eur Urol 2023; 84: 49–64
    1. Powles T, Valderrama BP, Gupta S et al. Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N Engl J Med 2024; 390: 875–888
    1. EAU Guidelines. Edn. presented at the EAU Annual Congress Paris 2024
    1. Knoll T, Omar MI, Maclennan S et al. Key steps in conducting systematic reviews for underpinning clinical practice guidelines: methodology of the European Association of Urology. Eur Urol 2018; 73: 290–300

MeSH terms

LinkOut - more resources